Trial
NCT00299390
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Bayer
Collaborators
—
Condition
Small Cell Lung Carcinoma
Intervention
Sagopilone (BAY86-5302, ZK 219477)
Why stopped
Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the trial due to lack of efficacy .
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-31